A Phase 3 interventional study of Risperidone ISM 75 mg and Risperidone ISM 100 mg in Acute Schizophrenia, sponsored by Rovi Pharmaceuticals Laboratories. Completed at 31 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-02-22.
Sponsored by Rovi Pharmaceuticals Laboratories · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 127 studies testing risperidone in Schizophrenia — 4 open to participants now, 4 under way, 2 of them phase 3. Risperidone · Schizophrenia.
Among the 127 studies testing risperidone in Schizophrenia, this one is the 13th largest by enrollment of the 123 interventional ones that give a count, is one of 3 that started in 2017, is one of 34 in phase 3, and was the 107th registered.
3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.
Browse Schizophrenia studies →4 of the 127 studies testing risperidone in Schizophrenia are open now, in 2 countries. Recruiting first, the newest first:
Minerva Neurosciences · Sites in United States
Ages 18–55
Northwell Health · Sites in United States, Canada
Ages 18–35
Louisiana State University Health Sciences Center Shreveport · Sites in United States
Ages 18–65
Centre for Addiction and Mental Health · Sites in Canada
Ages 18+
By country, each count listing its studies:
Risperidone: first FDA approval 1993 (RISPERDAL), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
127 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 7 · Phase 3 34 · Phase 4 63
First in 1996; this study’s year is marked. 3 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 438 is above the median of 71 across 2,947 interventional studies indexed under Schizophrenia.
Median enrollment 100 across the 123 interventional studies. Of the 106 that completed or were terminated, 30 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
63 of 127 have an industry lead sponsor. The 10 most frequent:
Rovi Pharmaceuticals Laboratories is the lead sponsor of 19 studies on the registry; 2 are open to participants now.
Rovi Pharmaceuticals Laboratories has 8 studies filed under Schizophrenia — fewer than ten, so there is no comparison to draw.
2 of the studies testing risperidone in Schizophrenia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06482554Phase 3Louisiana State University Health Sciences Center ShreveportLumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms. | 2026-12 |
| NCT04478838Centre for Addiction and Mental Health"Extended" (Alternate Day) Antipsychotic Dosing | 2027-09-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 127 studies testing risperidone in Schizophrenia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a multicenter, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of intramuscular (IM) injections of Risperidone ISM® (75 or 100 mg) or placebo, in patients with acute exacerbation of schizophrenia.
The study design includes a screening period, a 12-week treatment period, and a follow-up period. Eligible patients will be randomly assigned, under double-blind conditions, to receive the following study drug treatments in a 1:1:1 ratio during the double-blind treatment period: Risperidone ISM® 75 mg, Risperidone ISM® 100 mg, or placebo. The IM study drug (double-blind active Risperidone ISM® or placebo) will be administered in a deltoid or gluteal muscle for a total of 3 times, once every 4 weeks, during the 12-week treatment period.
If indicated for an individual patient, prohibited medications may be washed out during the screening period. Patients who have never taken Risperidone must have a brief trial of oral Risperidone in order to ensure a lack of any clinically significant hypersensitivity reactions before the first dose of the study drug is administered.
Efficacy will be assessed by describing changes in scores on standard psychiatric assessment tools at each visit. Safety assessments will also be conducted at each visit.
The primary objective of this study is the following:
The secondary objectives of this study are the following:
Patients who complete planned double-blind study drug treatments and study evaluations may be eligible to participate in an optional long-term extension segment of the study in which treatment with open-label Risperidone ISM 75 or 100 mg (randomly assigned) would begin immediately; for patients who do not participate in the extension segment, a safety follow-up phone contact will occur after the end-of-treatment visit.
In addition to patients continuing from the double-blind segment of the study (rollover patients), patients not previously enrolled in the study (de novo patients) may be eligible to enter the long-term extension segment of the study. These patients will be evaluated for eligibility at a screening visit and, if eligible, will be allocated to receive either 75 or 100 mg Risperidone ISM every 4 weeks for approximately 12 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
To be eligible for enrolment into the study, each patient must meet all of the following criteria at screening:
Capable of providing
Current diagnosis of schizophrenia, according to the , Fifth Edition (DSM-5) criteria
Positive and Negative Syndrome Scale (PANSS) results at the screening and baseline visits meets the following criteria:
a. Total score between 80 and 120, inclusive b. Score of ≥ 4 (moderate or greater) for ≥ 2 of the following Positive Scale items: i. Item 1 (P1: delusions) ii. Item 2 (P2: conceptual disorganization) iii. Item 3 (P3: hallucinatory behavior) iv. Item 6 (P6: suspiciousness/persecution)
Meets the following criteria:
a. If a sexually active, is using a medically accepted method, and will continue to use such throughout participation in this study (and for ≥ 6 months after the last dose of IM study drug has been administered); acceptable methods include the following: i. Condoms (male or female) with or without a spermicidal agent ii. Diaphragm or cervical cap with spermicide iii. Intrauterine device iv. Hormonal contraceptive b. If not currently sexually active, them meets the following criteria: i. Agrees that if sexually activity resumes while participating in this study, a medically accepted contraception method will be used
Exclusion Criteria:
An individual who meets any of the following criteria at screening will not be permitted to enroll in the study:
Clinically significant comorbid neuropsychiatric disorders including any of the following:
Clinically significant or unstable medical illness/condition/disorder that would be anticipated, in the investigator's opinion, to potentially compromise patient safety or adversely affect the evaluation of efficacy, including (but not necessarily limited to) the following:
i. History of seizure disorder or condition associated with seizures ii. History of brain tumor, subdural hematoma, or other clinically significant neurological condition within the past 12 months iii. Head trauma with loss of consciousness within 12 months before screening iv. Active acute or chronic central nervous system infection v. Stroke within 6 months before screening e. Cardiac conditions including the following: i. Clinically significant cardiac arrhythmia, cardiomyopathy, or cardiac conduction defect ii. History of myocardial infarction or unstable angina within the last 3 months before screening, or clinically significant abnormality on screening or baseline (ECG) including but not limited to the following: corrected for heart rate using Fridericia's formula (QTcF) > 465 msec if male or > 485 msec if female
Laboratory abnormality that, in the opinion of the investigator, would compromise the well-being of the patient, or any of the following laboratory abnormalities at screening or baseline:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients assigned to this arm will received 75 mg of Risperidone ISM during double-blind treatment period.
Drug: Risperidone ISM 75 mg
Patients assigned to this arm will received 100 mg of Risperidone ISM during double-blind treatment period.
Drug: Risperidone ISM 100 mg
Patients assigned to this arm will received placebo of Risperidone ISM during double-blind treatment period.
Drug: Placebo of Risperidone ISM
Monthly (once every 4 weeks) IM injection in the gluteal or deltoid muscle.
Also known as: Risperidone ISM
Monthly (once every 4 weeks) IM injection in the gluteal or deltoid muscle.
Also known as: Risperidone ISM
Monthly (once every 4 weeks) IM injection in the gluteal or deltoid muscle.
Also known as: PLACEBO
PANSS Total Score Mean Change From Baseline to Endpoint
The Positive and Negative Syndrome Scale (PANSS) is a 30-item clinician-rated instrument for assessing the symptoms of schizophrenia.The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score is the sum of all 30 PANSS items and ranges from 30 to 210, with 30 indicating absence of symptoms of schizophrenia and 210 indicating extreme ratings of all 30 symptoms. Negative change from baseline scores indicate improvements in symptoms whereas higher scores mean a worse outcome. Endpoint is defined as study day 85 or the last post-baseline assessment if early discontinuation.
Time frame: Day 1 (Baseline) and Day 85 (or the last post-baseline assessment)
CGI-S Total Score Mean Change From Baseline to Endpoint
The Clinician Global Impression - Severity (CGI-S) score is a 7-point clinician-rated scale for assessing the global severity of the illness. A rating of 1 is equivalent to "Normal, not at all ill" and a rating of 7 is equivalent to "Among the most extremely ill participants". Negative change from baseline scores indicate improvement in the severity of illness whereas higher scores mean a worse outcome. Endpoint is defined as study day 85 or the last post-baseline assessment if early discontinuation.
Time frame: Day 1 (Baseline) and Day 85 (or the last post-baseline assessment)
CGI-I Score Mean at Endpoint
The Clinical Global Impression - Improvement (CGI-I) Score consists of a single 7-point rating score total improvement, regardless of whether or not the change it is due entirely to drug treatment. Scores are: 1, Very much improved; 2, Much improved; 3, Minimally improved; 4, No change; 5, Minimally worse; 6, Much worse; or 7, Very much worse. Endpoint is defined as study day 85 or the last post-baseline double-blind assessment if early discontinuation.
Time frame: Day 1 (Baseline) and Day 85 (or the last post-baseline assessment)
Overall Response Rate at Endpoint
Overall response was defined as either PANSS total score ≥ 30% decrease from baseline, or CGI-I score of 2 (much improved) or 1 (very much improved). Endpoint is defined as study day 85 or the last post-baseline assessment if early discontinuation.
Time frame: Day 85 or the last post-baseline assessment
PANSS Response Rate at Endpoint
The definition of Positive and Negative Syndrome Scale (PANSS) response was a decrease from baseline in PANSS total score of ≥ 30% (improvement of symptoms). Endpoint is defined as study day 85 or the last post-baseline double-blind assessment if early discontinuation.
Time frame: Day 85 or the last post-baseline assessment
PANSS Positive Subscale Mean Change From Baseline to Endpoint
The PANSS consisted of three subscales that contained a total of 30 symptom constructs. For each symptom construct, severity is rated on a 7-point scale, with a score of 1 indicated the absence of symptoms and a score of 7 indicated extremely severe symptoms. In positive subscale, the 7 positive symptom constructs were: delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. PANSS Positive Subscale Score ranges from 7 (absence of symptoms) to 49 (extremely severe symptoms). Endpoint is defined as study day 85 or the last post-baseline assessment if early discontinuation.
Time frame: Day 1 (Baseline) and Day 85 (or the last post-baseline assessment)
PANSS Negative Subscale Mean Change From Baseline to Endpoint
The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 indicated- absence of symptoms and a score of 7 indicated- extremely severe symptoms. The PANSS negative subscale score was the sum of the rating scores for the 7 negative scale items from the PANSS panel. The 7 negative symptom constructs were: blunted affect, emotional withdrawal, poor rapport, passive apathetic withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation and stereotyped thinking. PANSS Negative Subscale Score ranges from 7 (absence of symptoms) to 49 (extremely severe symptoms). Endpoint is defined as study day 85 or the last post-baseline assessment if early discontinuation.
Time frame: Day 1 (Baseline) and Day 85 (or the last post-baseline assessment)
PANSS General Psychopathology Subscale Mean Change From Baseline to Endpoint
The PANSS consisted of three subscales that contained a total of 30 symptom constructs. For each symptom construct, severity is rated on a 7-point scale, with a score of 1 indicated the absence of symptoms and a score of 7 indicated extremely severe symptoms. The general psychopathology scale consists of 16 items which measure somatic concern, anxiety, guilt feelings, tension, mannerisms and posturing, depression, motor retardation, uncooperativeness, unusual thought content, disorientation, poor attention, lack of judgment and insight, disturbance of volition, poor impulse control, preoccupation and active social avoidance. PANSS General Psychopathology Subscale Score ranges from 16 (absence of symptoms) to 112 (extremely severe symptoms). Endpoint is defined as study day 85 or the last post-baseline assessment if early discontinuation.
Time frame: Day 1 (Baseline) and Day 85 (or the last post-baseline assessment)
PSP Total Score From Baseline at Each Post-baseline Assessment Time Point
Personal and Social Performance Scale (PSP) total score mean change from baseline at each post-baseline assessment time point. The PSP is a 100-point single-item rating scale that is based on 4 domains: family and social functioning, self-care, work and socially useful activities, and disturbing and aggressive behaviors. Each domain is rated in 6 degrees of severity (absent, mild, manifest, marked, severe, very severe). On the PSP scale, higher scores indicate better social functioning: 71-100 indicates mild to no functional impairment; 31-70 varying degrees of disability and 1-30, minimal functioning needing intense support and/or supervision. Participants with a PSP total score of 71 to 100 were considered to have mild functional difficulty. Scores of 31 to 70 represented varying degrees of disability (31 to 70) and ratings of 1 to 30 indicated minimal functioning that required intense support and/or supervision.
Time frame: Day 1 (Baseline), Days 29, 57 and 85 (or the last post-baseline assessment)
SWN-20 Total Score From Baseline at Each Post-baseline Assessment Time Point
20-item Subjective Well-Being Under Neuroleptics Treatment Scale (SWN-20) total score mean change from baseline at each post-baseline assessment time point. The SWN is a 38-item instrument to measure subjective effects of neuroleptic medications in patients with schizophrenia and consists of 20 positive statements and 18 negative statements. The short form of the SWN, the 20-item SWN-20, was developed in order to allow for quick assessment of subjective side effects in a clinical setting. Like in the original SWN, with the SWN-20 the patient is asked to rate well-being items that have been identified as related to antipsychotic treatment on a 6-point scale ranging from "Not at all" to "Very much." The SWN-20 is scored on a scale ranging from 20 to 120, with higher scores indicating better health-related quality of life (HRQL). The SWN-20 contains five 4-item subscales: mental functioning, self-control, emotional regulation, physical functioning, and social integration. Eac
Time frame: Day 1 (Baseline), Days 29, 57 and 85 or the last post-baseline assessment
Plasma PK Parameters
Plasma PK Parameters of Risperidone Active Moiety Cmax values are estimated and based on the plasma level of Day 3 for each dosing Interval; Cmin are the trough levels of Day 29, which is at the end of each dosing Interval;
Time frame: Day 3 and Day 29 after Dose 1, 2 and 3
| Milestone | Risperidone in Situ Microparticle (ISM) 75 mg | Risperidone ISM 100 mg | Placebo |
|---|---|---|---|
| Started | 144 | 146 | 147 |
| Completed | 107 | 95 | 88 |
| Not completed | 37 | 51 | 59 |
The Positive and Negative Syndrome Scale (PANSS) is a 30-item clinician-rated instrument for assessing the symptoms of schizophrenia.The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score is the sum of all 30 PANSS items and ranges from 30 to 210, with 30 indicating absence of symptoms of schizophrenia and 210 indicating extreme ratings of all 30 symptoms. Negative change from baseline scores indicate improvements in symptoms whereas higher scores mean a worse outcome. Endpoint is defined as study day 85 or the last post-baseline assessment if early discontinuation.
| units on a scale | Risperidone ISM 75 mg | Risperidone ISM 100 mg | Placebo |
|---|---|---|---|
| PANSS Total Score Mean Change From Baseline to Endpoint | -24.6 ± 1.51 | -24.7 ± 1.54 | -11.0 ± 1.56 |
The Clinician Global Impression - Severity (CGI-S) score is a 7-point clinician-rated scale for assessing the global severity of the illness. A rating of 1 is equivalent to "Normal, not at all ill" and a rating of 7 is equivalent to "Among the most extremely ill participants". Negative change from baseline scores indicate improvement in the severity of illness whereas higher scores mean a worse outcome. Endpoint is defined as study day 85 or the last post-baseline assessment if early discontinuation.
| units on a scale | Risperidone ISM 75 mg | Risperidone ISM 100 mg | Placebo |
|---|---|---|---|
| CGI-S Total Score Mean Change From Baseline to Endpoint | -1.3 ± 0.09 | -1.3 ± 0.09 | -0.6 ± 0.09 |
The Clinical Global Impression - Improvement (CGI-I) Score consists of a single 7-point rating score total improvement, regardless of whether or not the change it is due entirely to drug treatment. Scores are: 1, Very much improved; 2, Much improved; 3, Minimally improved; 4, No change; 5, Minimally worse; 6, Much worse; or 7, Very much worse. Endpoint is defined as study day 85 or the last post-baseline double-blind assessment if early discontinuation.
| units on a scale | Risperidone ISM 75 mg | Risperidone ISM 100 mg | Placebo |
|---|---|---|---|
| CGI-I Score Mean at Endpoint | 2.5 ± 0.10 | 2.5 ± 0.10 | 3.3 ± 0.10 |
Overall response was defined as either PANSS total score ≥ 30% decrease from baseline, or CGI-I score of 2 (much improved) or 1 (very much improved). Endpoint is defined as study day 85 or the last post-baseline assessment if early discontinuation.
| percentage of participants | Risperidone ISM 75 mg | Risperidone ISM 100 mg | Placebo |
|---|---|---|---|
| Overall Response Rate at Endpoint | 59.7 (50.7 to 68.2) | 54.3 (45.3 to 63.1) | 20.5 (13.9 to 28.3) |
The definition of Positive and Negative Syndrome Scale (PANSS) response was a decrease from baseline in PANSS total score of ≥ 30% (improvement of symptoms). Endpoint is defined as study day 85 or the last post-baseline double-blind assessment if early discontinuation.
| percentage of participants | Risperidone ISM 75 mg | Risperidone ISM 100 mg | Placebo |
|---|---|---|---|
| PANSS Response Rate at Endpoint | 41.9 (33.2 to 50.9) | 34.9 (26.7 to 43.8) | 9.1 (4.8 to 15.3) |
The PANSS consisted of three subscales that contained a total of 30 symptom constructs. For each symptom construct, severity is rated on a 7-point scale, with a score of 1 indicated the absence of symptoms and a score of 7 indicated extremely severe symptoms. In positive subscale, the 7 positive symptom constructs were: delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. PANSS Positive Subscale Score ranges from 7 (absence of symptoms) to 49 (extremely severe symptoms). Endpoint is defined as study day 85 or the last post-baseline assessment if early discontinuation.
| units on a scale | Risperidone ISM 75 mg | Risperidone ISM 100 mg | Placebo |
|---|---|---|---|
| PANSS Positive Subscale Mean Change From Baseline to Endpoint | -8.0 ± 0.49 | -8.7 ± 0.50 | -4.1 ± 0.50 |
The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 indicated- absence of symptoms and a score of 7 indicated- extremely severe symptoms. The PANSS negative subscale score was the sum of the rating scores for the 7 negative scale items from the PANSS panel. The 7 negative symptom constructs were: blunted affect, emotional withdrawal, poor rapport, passive apathetic withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation and stereotyped thinking. PANSS Negative Subscale Score ranges from 7 (absence of symptoms) to 49 (extremely severe symptoms). Endpoint is defined as study day 85 or the last post-baseline assessment if early discontinuation.
| units on a scale | Risperidone ISM 75 mg | Risperidone ISM 100 mg | Placebo |
|---|---|---|---|
| PANSS Negative Subscale Mean Change From Baseline to Endpoint | -3.8 ± 0.38 | -3.7 ± 0.39 | -1.7 ± 0.40 |
The PANSS consisted of three subscales that contained a total of 30 symptom constructs. For each symptom construct, severity is rated on a 7-point scale, with a score of 1 indicated the absence of symptoms and a score of 7 indicated extremely severe symptoms. The general psychopathology scale consists of 16 items which measure somatic concern, anxiety, guilt feelings, tension, mannerisms and posturing, depression, motor retardation, uncooperativeness, unusual thought content, disorientation, poor attention, lack of judgment and insight, disturbance of volition, poor impulse control, preoccupation and active social avoidance. PANSS General Psychopathology Subscale Score ranges from 16 (absence of symptoms) to 112 (extremely severe symptoms). Endpoint is defined as study day 85 or the last post-baseline assessment if early discontinuation.
| units on a scale | Risperidone ISM 75 mg | Risperidone ISM 100 mg | Placebo |
|---|---|---|---|
| PANSS General Psychopathology Subscale Mean Change From Baseline to Endpoint | -12.8 ± 0.79 | -12.4 ± 0.81 | -5.6 ± 0.82 |
Personal and Social Performance Scale (PSP) total score mean change from baseline at each post-baseline assessment time point. The PSP is a 100-point single-item rating scale that is based on 4 domains: family and social functioning, self-care, work and socially useful activities, and disturbing and aggressive behaviors. Each domain is rated in 6 degrees of severity (absent, mild, manifest, marked, severe, very severe). On the PSP scale, higher scores indicate better social functioning: 71-100 indicates mild to no functional impairment; 31-70 varying degrees of disability and 1-30, minimal functioning needing intense support and/or supervision. Participants with a PSP total score of 71 to 100 were considered to have mild functional difficulty. Scores of 31 to 70 represented varying degrees of disability (31 to 70) and ratings of 1 to 30 indicated minimal functioning that required intense support and/or supervision.
| score on a scale | Risperidone ISM | Placebo |
|---|---|---|
| Baseline | 49.93 (49 to 51) | 50.46 (49 to 52) |
| Study Day 29 | 59.03 (58 to 60) | 55.37 (54 to 57) |
| Study Day 57 | 61.33 (60 to 63) | 57.07 (55 to 59) |
| Study Day 85 | 60.60 (59 to 62) | 54.54 (53 to 56) |
20-item Subjective Well-Being Under Neuroleptics Treatment Scale (SWN-20) total score mean change from baseline at each post-baseline assessment time point. The SWN is a 38-item instrument to measure subjective effects of neuroleptic medications in patients with schizophrenia and consists of 20 positive statements and 18 negative statements. The short form of the SWN, the 20-item SWN-20, was developed in order to allow for quick assessment of subjective side effects in a clinical setting. Like in the original SWN, with the SWN-20 the patient is asked to rate well-being items that have been identified as related to antipsychotic treatment on a 6-point scale ranging from "Not at all" to "Very much." The SWN-20 is scored on a scale ranging from 20 to 120, with higher scores indicating better health-related quality of life (HRQL). The SWN-20 contains five 4-item subscales: mental functioning, self-control, emotional regulation, physical functioning, and social integration. Eac
| score on a scale | Risperidone ISM | Placebo |
|---|---|---|
| Baseline | 80.86 (79 to 83) | 80.28 (78 to 83) |
| Day 29 | 86.90 (85 to 89) | 83.23 (81 to 86) |
| Day 57 | 88.26 (87 to 90) | 86.32 (83 to 89) |
| Day 85 | 89.14 (88 to 91) | 85.50 (83 to 88) |
Plasma PK Parameters of Risperidone Active Moiety Cmax values are estimated and based on the plasma level of Day 3 for each dosing Interval; Cmin are the trough levels of Day 29, which is at the end of each dosing Interval;
| ng/mL | Risperidone ISM 75 mg | Risperidone ISM 100 mg |
|---|---|---|
| Dose 1/Estimated Cmax/Day 3 | 27.61 ± 19.992 | 32.00 ± 16.802 |
| Dose 1/Estimated Cmin/Day 29 | 19.21 ± 13.076 | 26.71 ± 14.960 |
| Dose 2/Estimated Cmax/Day 3 | 38.95 ± 22.381 | 53.44 ± 23.840 |
| Dose 2/Estimated Cmin/Day 29 | 17.46 ± 13.418 | 27.23 ± 14.070 |
| Dose 3/Estimated Cmax/Day 3 | 37.16 ± 19.504 | 50.09 ± 22.242 |
| Dose 3/Estimated Cmin/Day 29 | 20.16 ± 16.847 | 26.14 ± 16.343 |
Collected over Adverse event data were collected in all visits of the study, from the patient's signature of informed consent form through the end of study for each subject: Screening visit, Baseline (Day 1), Day 3, 4, 8, 15, 22, 29, 31, 43, 57, 59, 71, 85 and follow-up visit (Day 99).. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Risperidone ISM 75 mg | 0/144 (0%) | 2/144 (1.4%) | 101/144 (70.1%) |
| Risperidone ISM 100 mg | 0/146 (0%) | 5/146 (3.4%) | 119/146 (81.5%) |
| Placebo | 0/147 (0%) | 5/147 (3.4%) | 48/147 (32.7%) |
| Event | Risperidone ISM 75 mg | Risperidone ISM 100 mg | Placebo |
|---|---|---|---|
| SchizophreniaPsychiatric disorders | 1/144 | 2/146 | 4/147 |
| AppendicitisInfections and infestations | 1/144 | 0/146 | 0/147 |
| Skin infectionInfections and infestations | 0/144 | 1/146 | 0/147 |
| FallInjury, poisoning and procedural complications | 0/144 | 1/146 | 0/147 |
| Humerus fractureInjury, poisoning and procedural complications | 0/144 | 1/146 | 0/147 |
| AgitationPsychiatric disorders | 0/144 | 1/146 | 0/147 |
| Lower gastrointestinal haemorrhageGastrointestinal disorders | 0/144 | 0/146 | 1/147 |
| PneumoniaInfections and infestations | 0/144 | 0/146 | 1/147 |
| Event | Risperidone ISM 75 mg | Risperidone ISM 100 mg | Placebo |
|---|---|---|---|
| Blood prolactin increasedInvestigations | 13/144 | 21/146 | 0/147 |
| HeadacheNervous system disorders | 15/144 | 12/146 | 5/147 |
| HyperprolactinaemiaEndocrine disorders | 8/144 | 13/146 | 1/147 |
| AkathisiaNervous system disorders | 6/144 | 11/146 | 3/147 |
| Weight increasedInvestigations | 10/144 | 8/146 | 3/147 |
| Injection site painGeneral disorders | 8/144 | 4/146 | 5/147 |
| SomnolenceNervous system disorders | 4/144 | 8/146 | 4/147 |
| SchizophreniaPsychiatric disorders | 3/144 | 3/146 | 8/147 |
| Alanine aminotransferase increasedInvestigations | 4/144 | 7/146 | 3/147 |
| DizzinessNervous system disorders | 5/144 | 6/146 | 4/147 |
The efficacy analysis was performed on the mITT population containing all randomized patients who received ≥1 dose of study drug with a baseline measurement and ≥1 post-baseline evaluation for the PANSS, and for whom blinding was not potentially compromised owing to a one-off error in the interactive web response system (IWRS) used for randomized treatment assignment.
| Age, Continuous(years) | Risperidone ISM 75 mg | Risperidone ISM 100 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 42.6 ± 10.63 | 42.6 ± 11.14 | 40.0 ± 11.35 | 41.7 ± 11.08 |
| Sex: Female, Male(Participants) | Risperidone ISM 75 mg | Risperidone ISM 100 mg | Placebo | Total |
|---|---|---|---|---|
| Female | 41 | 45 | 47 | 133 |
| Male | 88 | 84 | 85 | 257 |
| Ethnicity (NIH/OMB)(Participants) | Risperidone ISM 75 mg | Risperidone ISM 100 mg | Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 6 | 3 | 10 | 19 |
| Not Hispanic or Latino | 123 | 126 | 122 | 371 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Risperidone ISM 75 mg | Risperidone ISM 100 mg | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 1 | 1 | 1 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 58 | 63 | 59 | 180 |
| White | 69 | 65 | 71 | 205 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 1 | 2 |
| Region of Enrollment(participants) | Risperidone ISM 75 mg | Risperidone ISM 100 mg | Placebo | Total |
|---|---|---|---|---|
| United States | 72 | 72 | 76 | 220 |
| Ukraine | 57 | 57 | 56 | 170 |
| Body Mass Index (BMI)(Kg/m^2) | Risperidone ISM 75 mg | Risperidone ISM 100 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 27.77 ± 5.226 | 28.26 ± 5.268 | 28.19 ± 4.715 | 28.07 ± 5.065 |
| Years since Schizophrenia Diagnosis(years) | Risperidone ISM 75 mg | Risperidone ISM 100 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 16.1 ± 10.67 | 15.7 ± 10.43 | 14.3 ± 9.74 | 15.4 ± 10.29 |
| Time since Acute Exacerbation or relapse (weeks)(days) | Risperidone ISM 75 mg | Risperidone ISM 100 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 3 ± 1.95 | 3 ± 3.67 | 3 ± 1.65 | 3 ± 2.55 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2017 to primary completion in Dec 2018, 18 months.
Results were first posted in Feb 2022, 3 years 1 month after primary completion. A results delay was requested in Dec 2019.
Of 99 industry-sponsored phase 3 interventional studies under Schizophrenia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 41. This study's 18 months is below that.
Counting every sponsor, half of 113 studies reached it within 32 months; a quarter within 20 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Risperidone
Rovi Pharmaceuticals Laboratories